Sarah Sorrel Named Independent Board Member at T-Heart

T-Heart has appointed Sarah Sorrel as its first independent board member. She joins the T-Heart Board of Directors as the company prepares its first in human/early feasibility study, bringing valuable experience and expertise to its execution.

Sorrel is the third female out of five representatives to join the board of T-Heart.

“We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah’s experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic,” CEO Soad El Ghazouani said.
 
Sorrel has more than 30 years of experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a European CRO, regulatory and reimbursement consultancy that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah earned a degree in engineering and applied science from Yale University. 
 
“I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next key step in the transcatheter heart valve field,” Sorrel said. “I look forward to contributing to T-Heart’s important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. “
 
T-Heart is a French medtech company focused on treating tricuspid regurgitation, a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The transcatheter tricuspid market represents a $3 billion-plus potential opportunity, although currently, limited treatment options exist to address this market. T-Heart has developed a differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges. The valve’s design enables interventional cardiologists to replace the diseased tricuspid valve with a simple one-step technique and allows for broad applicability to a larger patient population with minimal device sizes. 
 
T-Heart was co-founded in late 2018 with iBionext, a company builder and investor that supports and finances the development of companies with a strong technological breakthrough in health technology in Paris. T-Heart has successfully proved the concept through pre-clinical testing and initiated its Q-Sub for an early feasibility study with the U.S. Food and Drug Administration.